XenoPort announced that shipments of Horizant (gabapentin enacarbil) Extended-Release tablets to its distributor have commenced. Horizant is a prodrug of gabapentin that is indicated for postherpetic neuralgia and for moderate-to-severe primary restless legs syndrome in adults.
On May 1, 2013, XenoPort reacquired all commercialization rights to Horizant from GlaxoSmithKline. Prior to the reacquisition, GlaxoSmithKline experienced manufacturing issues and delays in April 2013 that resulted in a backorder of the 600mg extended-release tablets.
Horizant ER tablets are anticipated to be generally available to patients the first week of June.
For more information call (877) 936-6778 or visit Horizant.com.